Expression And Clinical Pathological Significance Of ER?HER-2 In Papillary Thyroid Cancer Coexist Breast Cancer

Objective:This study mainly research the expression of ER and HER-2 in papillary thyroid cancer coexist breast cancer,analysize the relationship between ER?HER-2 and clinicopathological features such as age,tumor size,pathological stage,and lymph node metastasis,and provide the new direction for the treatment of papillary thyroid cancer.Methods:To collect the patients from Yunnan Cancer Hospital during in May 2013 to July 2017,we select 45 cases of papillary thyroid cancer coexist breast cancer(double cancer group),31 cases of single papillary thyroid cancer(single cancer group),and 19 cases of benign thyroid disease(begnin group).All cases are selected by exclude and inclusion criteria.The clinical and pathological data of each group are true and complete.Immunohistochemistry is used to detect the expression of ER and HER-2 in papillary thyroid cancer tissues and benign thyroid diseases.Stastistical analysis is performed by using SPSS22.0 software package.Correlation analysis was performed using Spearman method.P<0.05 is statistically significant.Results:1.The positive rates of ER in double cancer group,single cancer group and benign group are 57.78%,70.97%and 5.26%.The positive rates of HER-2 in double group,single group and benign group are 37.78%,67.74%and 10.53%,The difference between the benign group and the other groups is statistically significant(P<0.05).There is no significant difference in the expression of ER between the single cancer group and the double cancer group.The positive expression rate of HER-2 in the single cancer group is higher than that in the double cancer group,and the difference is statistically significant(P<0.05).2.In the double cancer group,the expression of ER is not significantly different with the patient's age,tumor size,capsule infiltration,multifocal,bilateral primary,lymph node metastasis,pathological stage,and endocrine therapy.3.In the double cancer group,the expression of HER-2 in PTC patients aged<45 years is higher than that in PTC patients aged 45 years or older(p=0.015).The positive rate of HER-2 with lymph node metastasis is higher than that of no lymph node metastasis(P=0.039);The expression of HER-2 with tumor size,capsule infiltration,multifocal,bilateral primary,pathological stage absence,and targeted therapy is not significantly different.4.There is no relavence between papillary thyroid cancer ER expression and breast cancer ER expression in the double cancer group.The correlation analysis between HER-2 expression in the papillary thyroid cancer and HER-2 expression in breast cancer show r=0.328,P=0.028,indicating that in the double cancer group,the expression of HER-2 in breast cancer is positively relative with the expression of HER-2 in papillary thyroid cancer.5.In double cancer group,the correlation analysis of ER and HER-2 in papillary thyroid cancer show r=0.128,P=0.404,there is no relavence between ER expression and HER-2 expression of papillary thyroid cancer.Conclusions:1.The positive rates of ER and HER-2 are higher in the single cancer group and the double cancer group than the benign group.The positive rate of HER-2 is higher in the single cancer group than the double cancer group.2.In the double cancer group,the expression of HER-2 is related to age and lymph node metastasis.3.The expression of HER-2 in breast cancer is positively relative with the expression of HER-2 in papillary thyroid cancer.